PFIZER INC (PFE) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:PFE - US7170811035 - Common Stock
PFE Key Statistics, Chart & Performance
The current stock price of PFE is 25.71 USD. In the past month the price increased by 5.85%. In the past year, price decreased by -1.91%.
PFE Latest News, Press Relases and Analysis
PFE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 50.22 | 1.05T | ||
| JNJ | JOHNSON & JOHNSON | 20 | 499.88B | ||
| MRK | MERCK & CO. INC. | 11.88 | 261.34B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.51 | 100.25B | ||
| ZTS | ZOETIS INC | 20.14 | 56.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 23.23B | ||
| VTRS | VIATRIS INC | 4.57 | 12.40B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.28 | 11.58B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.68 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.53B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.52B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.37B |
Related stock screener links
About PFE
Company Profile
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
Company Info
PFIZER INC
66 Hudson Boulevard East
New York City NEW YORK 10017 US
CEO: Albert Bourla
Employees: 81000
Phone: 12127332323
PFIZER INC / PFE FAQ
What does PFIZER INC do?
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 81,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
What is the current price of PFE stock?
The current stock price of PFE is 25.71 USD. The price decreased by -0.04% in the last trading session.
Does PFIZER INC pay dividends?
PFIZER INC (PFE) has a dividend yield of 7.05%. The yearly dividend amount is currently 1.68.
What is the ChartMill rating of PFIZER INC stock?
PFE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the sector and industry classification for PFIZER INC?
PFIZER INC (PFE) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming dividend date for PFIZER INC?
The next ex-dividend date for PFIZER INC (PFE) is November 7, 2025.
Who owns PFIZER INC?
You can find the ownership structure of PFIZER INC (PFE) on the Ownership tab.
PFE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to PFE. When comparing the yearly performance of all stocks, PFE turns out to be only a medium performer in the overall market: it outperformed 51.14% of all stocks.
PFE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PFE. PFE has an excellent profitability rating, but there are some minor concerns on its financial health.
PFE Financial Highlights
Over the last trailing twelve months PFE reported a non-GAAP Earnings per Share(EPS) of 3.2. The EPS increased by 24.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.65% | ||
| ROA | 4.71% | ||
| ROE | 10.59% | ||
| Debt/Equity | 0.62 |
PFE Forecast & Estimates
30 analysts have analysed PFE and the average price target is 29.44 USD. This implies a price increase of 14.5% is expected in the next year compared to the current price of 25.71.
For the next year, analysts expect an EPS growth of -1.19% and a revenue growth -0.29% for PFE